COST-EFFECTIVENESS OF LIRAGLUTIDE FOR SUBJECTS WITH TYPE 2 DIABETES IN SPAIN

被引：0
|
作者：
Ramirz de Arellano, A. [1 ]
Hunt, B. [2 ]
Mezquita Raya, P. [3 ]
Briones, T. [1 ]
Perez, A. [1 ,4 ]
Valentine, W. J. [2 ]
机构：
[1] Novo Nordisk Pharma SA, Madrid, Spain
[2] Ossian Hlth Econ & Commun, Basel, Switzerland
[3] Hosp Torrecardenas, Clin San Pedro, Almeria, Spain
[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB69
引用
收藏
页码：A249 / A250
页数：2
相关论文
共 50 条
  • [31] Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain
    Pedro Mezquita-Raya
    Antonio Ramírez de Arellano
    Nana Kragh
    Gabriela Vega-Hernandez
    Johannes Pöhlmann
    William J. Valentine
    Barnaby Hunt
    Diabetes Therapy, 2017, 8 : 401 - 415
  • [32] COST-EFFECTIVENESS OF EXERCISE PROGRAMS IN TYPE 2 DIABETES
    Coyle, Doug
    Coyle, Kathryn
    Kenny, Glen P.
    Boule, Normand G.
    Wells, George A.
    Fortier, Michelle
    Reid, Robert D.
    Phillips, Penny
    Sigal, Ronald J.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (03) : 228 - 234
  • [33] Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes
    Ramos, Mafalda
    Ustyugova, Anastasia
    Hau, Nikco
    Lamotte, Mark
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (11) : 781 - 794
  • [34] Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study
    Zhang, Xuesong
    Liu, Sisi
    Li, Yukun
    Wang, Yan
    Tian, Meimei
    Liu, Guoqiang
    PLOS ONE, 2016, 11 (06):
  • [35] Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States
    Hunt, B.
    McConnachie, C. C.
    Gamble, C.
    Dang-Tan, T.
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (11) : 1117 - 1120
  • [36] COST-EFFECTIVENESS ANALYSIS OF LIRAGLUTIDE VERSUS INSULIN GLARGINE IN CHINESE PATIENTS WITH TYPE 2 DIABETES INSUFFICIENTLY CONTROLLED ON METFORMIN
    Gu, X.
    Liu, F.
    Men, P.
    Zhai, S.
    VALUE IN HEALTH, 2018, 21 : S75 - S75
  • [37] EVALUATING THE LONG-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE 1.2 MG AND EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Shi, L. W.
    Han, S.
    Liu, F.
    VALUE IN HEALTH, 2014, 17 (07) : A744 - A745
  • [38] Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States
    Reifsnider, Odette
    Pimple, Pratik
    Stargardter, Matthew J. D.
    Brand, Sarah
    Desai, Nihar
    Shetty, Sharash
    DIABETES, 2020, 69
  • [39] EFFECT OF VARYING MODELLING ASSUMPTIONS ON THE COST-EFFECTIVENESS OF LIRAGLUTIDE 1.2 MG (AS A COMPONENT OF DUAL THERAPY) IN TYPE 2 DIABETES
    Valentine, W. J.
    Chubb, B. D.
    Smith, I. C.
    VALUE IN HEALTH, 2010, 13 (07) : A290 - A291
  • [40] Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review
    Zueger, Patrick M.
    Schultz, Neil M.
    Lee, Todd A.
    PHARMACOECONOMICS, 2014, 32 (11) : 1079 - 1091
12345